9 results about "Bleeding time" patented technology

The invention relates to the technical field of medical materials, and discloses a chitosan-based antibacterial dressing and a preparation method thereof. The antibacterial dressing comprises an adhesive tape layer, a dressing surface layer and a protective film, functional dressing liquid is adsorbed on the dressing surface layer, and the functional dressing liquid is prepared from, by weight, 2-4 parts of propolis extract, 1-3 parts of glycerinum, 1-3 parts of alginate oligosaccharide, 0.5-1 part of carbomer, 0.001-0.005 part of growth factors, 2-4 parts of modified chitosan and 3-6 parts of modified gelatin. The modified chitosan is grafted with borneol base and long-chain pyridinium salt, so that reproduction of common pathogenic bacteria can be efficiently and continuously inhibited, and wound infection is prevented; the modified gelatin can shorten the bleeding time of the wound surface and reduce the bleeding amount, and the dressing has good biocompatibility and biodegradability.

The utility model discloses a compression hemostasis device acting in the body in the technical field of first-aid hemostasis, which is characterized in that a hemostasis bag is added, a hemostasis tube is connected with the hemostasis bag, the hemostasis bag can extend into the body of a patient and can be pressurized and expanded to perform compression hemostasis on a wound part in the body, and a hemostasis clamping piece is added outside, so that the hemostasis effect is good. The hemostasis device can be attached to the in-vitro skin, compression hemostasis is carried out on the body surface through the hemostasis clamping piece, meanwhile, the hemostasis clamping piece and the hemostasis bag can be clamped inside and outside, a body surface bleeding opening is clamped and blocked, and effective hemostasis is carried out on a bleeding point through the inner layer and the outer layer. In addition, the blood collection tube is additionally arranged for observing the bleeding amount, bleeding spots can be located more quickly, the bleeding duration is shortened, and time is won for follow-up treatment.

The invention discloses a Yao medicine composition with effects of regulating menstruation and stopping bleeding as well as a preparation method and application of the Yao medicine composition, and belongs to the technical field of ethnic medicines. The composition is prepared from paris polyphylla, radix zanthoxyli, giantleaf ardisia rhizome, ovateleaf holly bark, radix fici simplicissimae and callicarpa macrophylla. The preparation method comprises the following steps: carrying out secondary water extraction on the raw materials, concentrating to specified density, standing, precipitating, removing impurities, preparing and the like. The Yao medicine composition disclosed by the invention not only has a remarkable hemostatic effect, but also has an excellent endocrine regulation function. Pharmacodynamic experiments show that in a rat dysfunctional blood model induced by combination of mifepristone and misoprostol, the composition can significantly reduce the bleeding amount and shorten the bleeding time, the hemostatic effect is equivalent to that of a positive control drug, namely Gongxuening capsule and a pure paris polyphylla extract, and although a paris polyphylla preparation exists, the hemostatic effect of the composition is remarkably improved. However, the problem that a single paris polyphylla preparation is weak in FSH / LH regulation capacity is solved, and data prove that the compound is irreplaceable.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The application belongs to the technical field of traditional Chinese medicines, and specifically discloses a traditional Chinese medicine toothpaste with the functions of relieving inflammation and stopping bleeding. The traditional Chinese medicine toothpaste contains 0.1-1% of a traditional Chinese medicine polysaccharide composition and 65-85% of toothpaste raw materials and auxiliaries, and the rest is solvent; the traditional Chinese medicine polysaccharide composition contains ginger-prepared moslae polysaccharide; the traditional Chinese medicine polysaccharide composition can significantly reduce the bleeding time of mice and the swelling degree of the feet of rats, and achieve the functions of relieving inflammation and stopping bleeding. If the ginger-prepared moslae polysaccharide and the coralline polysaccharide are matched at a mass ratio of 1:0.5-1, the functions of relieving inflammation and stopping bleeding are better.

This invention discloses a robot-assisted electrocoagulation hemostasis system, comprising: an image processing module for acquiring preoperative and intraoperative three-dimensional images of the patient's affected area and performing registration; an optical tracking module for acquiring the poses of the patient's optical array, the registered optical array, and the tool's optical array; a navigation registration module for performing navigation registration based on the registration and the poses of each optical array to obtain the positional relationship between the preoperative image and the patient's optical array; an image processing module for acquiring images obtained by endoscopy, identifying and acquiring bleeding points and their corresponding bleeding times; and a planning and execution module for planning the target pose of the robotic arm and the electrocoagulation tool mounted at its end based on telecentric fixed point constraints, and executing accordingly. This invention, through automatic robot navigation control, quickly and accurately guides the system to the bleeding point, reducing the surgeon's workload and avoiding efficiency issues caused by unfamiliar human operation.

The invention belongs to the technical field of application of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating dysfunctional uterine bleeding. Pharmacological experiments prove that Dan'e'fukang can shorten the blood coagulation time and bleeding time of mice, and increase the uterine coefficient, estradiol level and progesterone level of rats without ovulation type dysfunctional uterine bleeding and the VEGF protein expression quantity of endometrial tissues of the rats. The Dan'e Fukang provides more medication choices for clinical treatment of dysfunctional uterine bleeding diseases, and has the advantages of good effect, many years of clinical use experience and high safety.

Inventors show that both iKO and Eng+ / - experienced increased bleeding compared to WT mice (longer bleeding times, more rebleeding events, greater hemoglobin loss, p<0.05). Treatment with pEng effectively reduced bleeding in all genotypes (p<0.05), reverting to the control WT condition. Furthermore, pEng induced strong platelet aggregation in both murine and human platelets compared to controls (p<0.01), demonstrating its efficacy in promoting hemostasis. No differences were found in term of co-culture, wound healing and sprouting considering controls and endoglin siRNA ECs, while a beneficial effect on ENG-free endothelial cells was found in capillary flow conditions, restoring the control condition. Accordingly, pEng appears to be a promising treatment for epistaxis in HHT, without deleterious effect on EC tested functions. The present invention relates to a peptide derived from endoglin (pEng) comprising at least the amino acid sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10 (SEQ ID NO: 1) wherein X1 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X2 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X3 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X4 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X5 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X6 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X7 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X8 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X9 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), X10 is Phe (F), Tyr(Y), His(H), Thr(T), Ser(S), Leu(L), or Val (V), Wherein peptide derived from endoglin (pEng) comprises at least one of each Phe(F), Leu(L), Tyr(Y), His(H), Thr(T), Ser(S), and Val(V).

The invention provides application of adipose-derived stem cell artificial nano-vesicles in preparation of drugs for promoting platelet generation. The invention also provides an adipose-derived stem cell artificial nano-vesicle loaded with a sanguisorba monomer DMAG, and the adipose-derived stem cell artificial nano-vesicle is prepared by extracting a cell membrane of adipose-derived stem cells and entrapping DMAG by using a natural phospholipid bilayer structure of the cell membrane so as to form a nano-sized vesicle structure. The artificial nano-vesicle inherits good biocompatibility of adipose-derived stem cells, can effectively reduce immunological rejection of an organism, and protects DMAG from degradation effects such as in-vivo enzymolysis and the like; and a protective delivery system can be formed in vivo, so that rapid metabolism and elimination of DMAG in vivo are reduced, and the effective release time of DMAG in vivo is prolonged. The artificial nano-vesicles significantly increase the number of peripheral blood platelets, shorten the bleeding time and reduce the immunogenicity at the same time.